Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis

Rheumatology
Peter C Taylor

Abstract

Tofacitinib and baricitinib are the first orally available, small-molecule inhibitors of Janus kinase (JAK) enzymes to be approved for the treatment of RA. Tofacitinib is a selective JAK1, 3 inhibitor with less activity against JAK2 and TYK2 and baricitinib is a selective, oral JAK1, 2 inhibitor with moderate activity against TYK2 and significantly less activity against JAK3. Both drugs have undergone extensive phase III clinical trials in RA and demonstrated rapid improvements in disease activity, function and patient-reported outcomes as well as disease modification. Tofacitinib 5 mg bd, was approved by the Federal Drug Administration in 2012 for the treatment of RA in patients who are intolerant or unresponsive to MTX. An extended release formulation for the treatment of RA was approved by Federal Drug Administration in 2016. In 2017 the European Medicines Agency approved tofacitinib 5 mg bd in combination with MTX and baricitinib 4 mg and 2 mg once daily for the treatment of moderate to severe active RA in adult patients who are intolerant or unresponsive to one or more conventional synthetic DMARDs.

References

Apr 7, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jordan S FridmanKris Vaddi
Aug 10, 2012·The New England Journal of Medicine·Roy FleischmannUNKNOWN ORAL Solo Investigators
Aug 10, 2012·The New England Journal of Medicine·Ronald F van VollenhovenUNKNOWN ORAL Standard Investigators
Dec 12, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Kate Traynor
Mar 14, 2013·Annals of the Rheumatic Diseases·Iain B McInnesJohn D Bradley
Jan 15, 2014·Journal of Medicinal Chemistry·James D ClarkJean-Baptiste Telliez
Jun 19, 2014·The New England Journal of Medicine·Eun Bong LeeUNKNOWN ORAL Start Investigators
Feb 18, 2015·Nature Reviews. Rheumatology·Josef S Smolen, Daniel Aletaha
May 15, 2015·Annals of the Rheumatic Diseases·Josef S SmolenDesirée van der Heijde
Nov 8, 2015·Arthritis Care & Research·Jasvinder A SinghTimothy McAlindon
Mar 20, 2016·Current Opinion in Chemical Biology·Kunihiro Yamaoka
Mar 31, 2016·The New England Journal of Medicine·Mark C GenoveseJosef S Smolen
Jul 23, 2016·Seminars in Arthritis and Rheumatism·Christina Charles-SchoemanRichard Riese
Feb 16, 2017·The New England Journal of Medicine·Peter C TaylorYoshiya Tanaka
Jul 25, 2017·Expert Opinion on Pharmacotherapy·Christophe RichezBernard Bannwarth
Feb 22, 2018·Annals of the Rheumatic Diseases·Peter C TaylorIain B McInnes

❮ Previous
Next ❯

Citations

Aug 6, 2019·Dermatologic Therapy·Ana B de OliveiraJoão Maia-Silva
Nov 27, 2019·Cancers·Linus WahnschaffeMarco Herling
Dec 14, 2019·Nature Reviews. Rheumatology·Kathryn M KingsmorePeter E Lipsky
Sep 6, 2019·Journal of Cellular Physiology·Nicola MaruottiFrancesco Paolo Cantatore
Jun 10, 2020·Expert Opinion on Pharmacotherapy·Eduardo Mysler, Ana Lizarraga
Aug 14, 2020·Experimental & Molecular Medicine·Natalie A Sims
Jun 5, 2020·Nature Reviews. Rheumatology·Anne Grete SembSilvia Rollefstad
Aug 1, 2020·Expert Opinion on Biological Therapy·Mrinalini DeyRobert J Moots
Jun 14, 2020·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Enriqueta Vallejo-YagüeAndrea M Burden
Jul 12, 2019·Frontiers in Medicine·Vasco C Romão, João Eurico Fonseca
Sep 10, 2020·Frontiers in Immunology·Daniel R BurrageNidhi Sofat
Sep 29, 2020·Journal of Inflammation Research·Robert HarringtonRichard Conway
Jun 20, 2020·Clinical Reviews in Allergy & Immunology·Jiao JiangQianjin Lu
Apr 30, 2020·Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Società Italiana Di Dermatologia E Sifilografia·Arvin IghaniJensen Yeung
Dec 10, 2020·Expert Opinion on Drug Metabolism & Toxicology·Karima AlimOlivier Fardel
Nov 14, 2020·Clinical Reviews in Allergy & Immunology·Hao Li, George C Tsokos
Dec 29, 2020·Frontiers in Medicine·Francesca IngegnoliRoberto Caporali
Jan 19, 2021·Biosafety and Health·Marzuq A UngogoGarba M Khalid
Mar 9, 2021·Therapeutic Advances in Ophthalmology·Judy L ChenEdmund Tsui
Jun 14, 2020·Joint, Bone, Spine : Revue Du Rhumatisme·Cristina GarufiFabrizio Conti
Apr 14, 2021·Expert Review of Clinical Pharmacology·Maria Gabriella RaimondoEnnio Giulio Favalli
May 6, 2021·Rheumatology·Francesca Romana SpinelliMassimo Gadina
Jun 10, 2021·Open Access Rheumatology : Research and Reviews·Eduardo MyslerAna Lizarraga
Aug 6, 2021·ImmunoTargets and Therapy·Sarah UnterbergerSandra Sacre

❮ Previous
Next ❯

Software Mentioned

ORAL Step
ORAL Start
ORAL Strategy
BALANCE
ORAL Solo
ORAL Standard
ORAL Sync
BEYOND
ORAL
RA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.